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 3 
Abstract (241 words) 1 
Increased stiffness in the extracellular matrix (ECM) contributes to tumor progression and 2 
metastasis. Therefore, stromal modulating therapies and accompanying biomarkers are 3 
being developed to target ECM stiffness. Magnetic resonance (MR) elastography can 4 
noninvasively and quantitatively map the viscoelastic properties of tumors in vivo and thus 5 
has clear clinical applications. Herein, we used MR elastography, coupled with 6 
computational histopathology, to interrogate the contribution of collagen to tumor 7 
biomechanical phenotype and evaluate its sensitivity to collagenase-induced stromal 8 
modulation. Elasticity (Gd) and viscosity (Gl) were significantly greater for orthotopic BT-474 9 
(Gd=5.9±0.2kPa, Gl=4.7±0.2kPa, n=7) and luc-MDA-MB-231-LM2-4 (Gd=7.9±0.4kPa, 10 
Gl=6.0±0.2kPa, n=6) breast cancer xenografts, and luc-PANC1 (Gd=6.9±0.3kPa, 11 
Gl=6.2±0.2kPa, n=7) pancreatic cancer xenografts, compared to tumors associated with the 12 
nervous system, including GTML/Trp53KI/KI medulloblastoma (Gd=3.5±0.2kPa, 13 
Gl=2.3±0.2kPa, n=7), orthotopic luc-D-212-MG (Gd=3.5±0.2kPa, Gl=2.3±0.2kPa, n=7), luc-14 
RG2 (Gd=3.5±0.2kPa, Gl=2.3±0.2kPa n=5) and luc-U-87-MG (Gd=3.5±0.2kPa, 15 
Gl=2.3±0.2kPa n=8) glioblastoma xenografts, intracranially propagated luc-MDA-MB-231-16 
LM2-4 (Gd=3.7±0.2kPa, Gl=2.2±0.1kPa, n=7) breast cancer xenografts, and Th-MYCN 17 
neuroblastomas (Gd=3.5±0.2kPa, Gl=2.3±0.2kPa, n=5). Positive correlations between both 18 
elasticity (r=0.72, p<0.0001) and viscosity (r=0.78, p<0.0001) were determined with collagen 19 
fraction, but not with cellular or vascular density. Treatment with collagenase significantly 20 
reduced Gd (p=0.002) and Gl (p=0.0006) in orthotopic breast tumors. Texture analysis of 21 
extracted images of picrosirius red staining revealed significant negative correlations of 22 
entropy with Gd (r=-0.69, p<0.0001) and Gl (r=-0.76, p<0.0001), and positive correlations of 23 
fractal dimension with Gd (r=0.75, p<0.0001) and Gl (r=0.78, p<0.0001). MR elastography 24 
can thus provide sensitive imaging biomarkers of tumor collagen deposition and its 25 
therapeutic modulation. 26 
 27 
Significance (17 words) 28 
 29 
MR elastography enables non-invasive detection of tumor stiffness and will aid in the 30 
development of ECM-targeting therapies. 31 
 32 
 33 
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Aberrant tensional homeostasis and increased stiffness are hallmarks of cancer. The origin 3 
of elevated tumor stiffness is not fully understood, but may often reflect increased 4 
mechanical stress associated with rapid tissue expansion and compressed vasculature and 5 
lymphatics, and extracellular matrix (ECM) rigidity. There is much evidence showing that 6 
increased tissue stiffness contributes to malignant transformation, tumor progression and 7 
metastasis (1,2). The elevated solid stress and interstitial fluid pressure (IFP) that may drive 8 
increased tumor stiffness are also two major obstacles to efficient tumor drug delivery (3).   9 
 10 
Both breast and pancreatic cancers are characterized by excessive desmoplastic stromal 11 
reaction and dense ECM (4,5). Collagen, the principal component of the fibrillary protein 12 
network within the ECM, is the major contributor to ECM stiffening, is strongly implicated in 13 
tumor evolution and progression, and is associated with poor patient prognosis (6-9). 14 
Increased collagen deposition and enhanced matrix cross-linking occurs with progressive 15 
structural remodeling of the ECM scaffold which facilitates tumor growth (9). Suppression of 16 
collagen synthesis inhibits tumor growth and metastasis, and enhances drug penetration 17 
(10). 18 
 19 
Significant efforts are currently focused on targeting tumor ECM stiffness for therapeutic gain 20 
(2,4,11-13). The development of stromal modulating therapies would benefit from non-21 
invasive imaging biomarkers to inform on changes associated with therapeutic efficacy. A 22 
number of innovative magnetic resonance (MR) and ultrasound (US) imaging techniques are 23 
being exploited to image the viscoelastic and other mechanical properties of tissue in vivo 24 
(14-17). One approach, MR elastography, is being used to visualize and measure tissue 25 
elasticity and viscosity in vivo. MR elastography yields quantitative images, and therefore 26 
imaging biomarkers, that map the absolute value of the complex shear modulus G* in terms 27 
of its two components, the elasticity modulus Gd (a measure of the ability of an object to 28 
resume a normal shape after being stretched or compressed) and the viscosity modulus Gl 29 
(a measure of resistance to gradual deformation by shear or tensile stress). We and others 30 
have demonstrated, in pre-clinical tumor models and cancer patients in vivo, the potential of 31 
the MR elastography-derived mechanical phenotype to inform on the underlying tumor 32 
microstructure and treatment-induced changes to its integrity (18-25). 33 
 34 
Early imaging biomarker development demands close imaging-pathology correlation to 35 
understand the biological processes underpinning the imaging measurement, which can be 36 
meaningfully studied using animal models (26-28). The systematic evaluation of tumor 37 
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 5 
stromal components and their contribution to tissue stiffness as measured by MR 1 
elastography is in its infancy. This study describes the use of MR elastography, coupled with 2 
computational histopathology, to interrogate the contribution of the collagen network to the 3 
biomechanical phenotype imaged in vivo in a wide range of orthotopically-propagated and 4 
spontaneously arising transgenic models with disparate pathologies. The sensitivity of MR 5 
elastography to monitor stromal modulation in vivo following administration of collagenase is 6 
also demonstrated. 7 
 8 
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Materials and Methods 1 
 2 
Cells   3 
All cell lines used in this study tested negative for mycoplasma infection at the time of tumor 4 
implantation and human cells were authenticated by short tandem repeat (STR) profiling. 5 
Their origins, provenance and culture conditions are summarized in Supplementary Table 1 6 
and 2. 7 
 8 
Animals & Tumor Models  9 
All animal experiments were approved by The Institute of Cancer Research Animal Welfare 10 
and Ethical Review Body, and performed in accordance with the UK Home Office Animals 11 
(Scientific Procedures) Act 1986, the United Kingdom National Cancer Research Institute 12 
guidelines for the welfare of animals in cancer research (29), and reported according to the 13 
ARRIVE (animal research: reporting in vivo experiments) guidelines (30). Mice were housed 14 
in specific pathogen-free rooms in autoclaved, aseptic microisolator cages with a maximum 15 
of 5 animals per cage. Mice were allowed access to sterile food and water ad libitum. A total 16 
of 84 mice were enrolled and a summary of the in vivo models used in this study is 17 
presented in Table 1. 18 
 19 
Intracranial tumor propagation 20 
Human luc-U-87 MG glioblastoma (5 x 104), rat luc-RG2 glioma (5 x 103), human luc-D-212 21 
MG pediatric hemispheric giant-cell glioblastoma (5 x 103), or human metastatic luc-MDA-22 
MB-231 LM2-4 breast cancer (5 x 103) cells were implanted supratentorially in the brains of 23 
adult female athymic NCr-Foxn1nu mice (Charles River, Margate, UK) as previously 24 
described (19). Animals were anesthetized using 1-2% isoflurane in oxygen (1 l/min). A ~1 25 
cm incision was made in the skin on the top of the head, and a 1mm hole drilled using a 26 
surgical bone microdrill (Harvard Apparatus, Edenbridge, UK). Cell suspension (5 μl) was 27 
then injected at a depth of 3 mm from the dura, at a rate of 2 μl/min, using a 10 μl syringe 28 
(VWR International, Lutterworth, UK) and a nanomite syringe pump (Harvard Apparatus). 29 
The needle was removed 3 minutes after completion of the injection and the skin repaired 30 
with Vetbond™ Tissue Adhesive (3M Animal Care Products, St Paul, MN, USA).  31 
 32 
Tumor establishment and growth were monitored with bioluminescence imaging (BLI) using 33 
a Xenogen IVIS® 200 system coupled with LivingImage software (Caliper Life Sciences, 34 
Runcorn, UK). Luciferin (150mg/kg, Caliper Life Sciences) was administered 35 
intraperitoneally 10 minutes before imaging. MR elastography was performed when the BLI 36 
photon flux reached a threshold value previously determined to represent a tumor of 37 
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 7 
approximately 30-40 mm3, a volume considered of sufficient size to acquire MR 1 
elastography data but not large enough to cause neurological effects in the mice. The 2 
average time from implantation to imaging was 18 days for the luc-U-87 MG and luc-MDA-3 
MB-231 LM2-4 tumors, 22 days for the luc-RG2 tumors and 45 days for the luc-D-212 MG 4 
glioblastomas. 5 
 6 
GTML/Trp53KI/KI transgenic model of medulloblastoma 7 
The generation of the GTML/Trp53KI/KI mice has been previously reported (31). Mice were 8 
genotyped to detect the presence of human MYCN and Trp53 transgenes. Male and female 9 
mice were monitored twice weekly for the development of a BLI signal from the midbrain. 10 
MR elastography was performed when the photon flux reached a threshold value previously 11 
determined to represent a tumor of approximately 20-30 mm3. 12 
 13 
Th-MYCN transgenic model of neuroblastoma 14 
Transgenic Th-MYCN mice were genotyped to detect the presence of the human MYCN 15 
transgene (27). Both male and female hemizygous mice were used, which spontaneously 16 
developed palpable abdominal tumors between 50–130 days with a 25% penetrance. Tumor 17 
progression was monitored weekly by palpation by an experienced technician until the tumor 18 
reached a diameter greater than ~5 mm, at which point they underwent MR elastography. 19 
 20 
Subcutaneous U87-MG xenografts 21 
Adult female NCr-Foxn1nu mice were injected subcutaneously in the flank with 2 x 106 luc-U-22 
87-MG cells. Tumor development was monitored weekly by caliper measurements, and MR 23 
elastography performed when tumors reached a diameter of ~7 mm. 24 
 25 
Orthotopic models of breast and pancreatic cancer 26 
Human luc-MDA-MB-231 LM2-4 or BT-474 breast cancer cells (5 x 106) were injected into 27 
the third abdominal fat pad of adult female NCr-Foxn1nu mice (100 µl cell suspension in PBS 28 
and matrigel (1:1)). A 17β-estradiol pellet (60-day release, Innovative Research of America, 29 
Sarasota, FL, USA) was implanted in the neck nape one day before implantation of BT-474 30 
cells. Tumor development was monitored weekly by caliper measurements, and MR 31 
elastography performed when tumors reached a diameter of ~7 mm. 32 
 33 
For the orthotopic propagation of pancreatic cancer xenografts, a small incision was made 34 
on the left flank of adult female athymic CD1-Foxn1nu mice (Charles River, Margate, UK) 35 
through the skin and peritoneum, the pancreas exteriorized, and human luc-Panc-1 (1 x 36 
107 cells in suspension in PBS and matrigel (1:1)) injected using a Hamilton syringe. The 37 
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pancreas was then returned into the abdominal cavity and the incision sutured. Successful 1 
engraftment and tumor progression were confirmed using BLI, and MR elastography 2 
performed ~90 days post-implantation. 3 
 4 
Response to Collagenase 5 
Orthotopic parental MDA-MB-231 and BT-474 breast cancer xenografts were propagated as 6 
described above. MR elastography was performed on established tumors 24 hours prior to 7 
and 5 hours after intravenous treatment with either collagenase (62U/kg, bacterial 8 
collagenase from Clostridium histolyticum, Sigma-Aldrich, UK) or saline. 9 
 10 
MRI and MR elastography data acquisition and analysis 11 
MRI was performed on a 7T horizontal bore MicroImaging system (Bruker, Ettlingen, 12 
Germany) using a 3cm birdcage volume coil. Tumor-bearing mice were anesthetized with a 13 
10ml/kg intraperitoneal injection of fentanyl citrate (0.315mg/ml) plus fluanisone (10mg/ml 14 
(Hypnorm; Janssen Pharmaceutical Ltd., High Wycombe, UK)), midazolam (5mg/ml 15 
(Hypnovel; Roche)), and sterile water (used at a ratio of 1:1:2). The mouse core temperature 16 
was maintained at 37°C with warm air blown through the magnet bore. 17 
 18 
Anatomical T2-weighted images (using a rapid acquisition with refocused echoes (RARE) 19 
sequence, with TE = 36ms, TR = 4.5s, RARE factor = 8, 40 contiguous 1mm thick 20 
transverse slices, 1 average, matrix size 128×128 over a 3×3cm field of view (FOV)) were 21 
used to localize and determine the tumor volume, plan the MR elastography acquisition, and 22 
optimize the local field homogeneity over the region of interest (ROI) using the FASTMAP 23 
algorithm. 24 
 25 
MR elastography was performed as previously described (18,19). The mechanical 26 
vibrations, generated by an electromagnetic shaker (Brüel & Kjaer, Nærum, Denmark), were 27 
transmitted through a flexible nylon rod to either i) a square piston with a concave curved 28 
face positioned on the mouse head for intracranial tumors, or directly on the skin over 29 
subcutaneous luc-U87-MG tumors and orthotopically propagated breast cancer xenografts, 30 
or ii) a round flat-faced piston placed on the abdomen above a palpated tumor (Th-MYCN or 31 
orthotopic pancreatic tumor), all positioned within the volume coil at the isocenter of the 32 
magnetic field. MR elastography was performed using mechanical excitations at a vibration 33 
frequency of 1000 Hz, exciting the shaker with a voltage that generated mechanical waves 34 
inside the tumor with amplitude greater than 0.5 µm. A 2D spin-echo sequence incorporating 35 
sinusoidal motion-sensitizing gradients synchronized to the mechanical excitation was used. 36 
Data were acquired in 3 orthogonal directions, from 10 contiguous transverse slices (300 µm 37 
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thick), using 2 averages of 64 phase encoding steps over a 1.92×1.92 cm FOV, with TE = 27 1 
ms, TR = 1001 ms and 8 time sampling steps, giving an isotropic spatial sampling of 2 
300×300×300 µm of the mechanical wave propagation displacement inside the tumor. The 3 
total acquisition time was ~ 51 min. Finally, high resolution T2-weighted RARE images were 4 
acquired from the same ten contiguous transverse slices, (TE = 36 ms, TR = 4.5 s, RARE 5 
factor = 8, 300 µm thick, 10 averages, matrix size 128×128 over a 1.92×1.92cm FOV). 6 
 7 
Image Reconstruction and Analysis. Parametric maps of the absolute value of the complex 8 
shear modulus |G*|, elasticity Gd and viscosity Gl (where |G*| = Gd+ iGl) were reconstructed 9 
using in-house software from the three-dimensional displacement vector measured as 10 
described above, and using the following equation (32): 11 
−𝜌𝜔2?⃗? =  𝐺∗∇2?⃗? , , 12 
where  is the complex-valued curl of the measured displacement field , ρ is the density of 13 
the material and ω is the angular frequency. For each slice, Gd and Gl (kPa) were 14 
determined pixelwise from a ROI covering the whole tumor delineated from the high 15 
resolution T2-weighted images.   16 
 17 
Computational histopathology 18 
 19 
Tissue preparation: Guided by the T2-weighted MR images, tumors were carefully excised 20 
and orientated for subsequent histopathological processing. Adjacent formalin-fixed paraffin 21 
embedded sections (3 μm) were cut and tinctorially stained with picrosirius red (for collagen I 22 
and III), hematoxylin and eosin (H&E, for cellularity), or immunohistochemically processed 23 
for detection of the murine vascular endothelial marker CD31 (rabbit EP3095, Millipore, 24 
Watford, UK), using diaminobenzidine (DAB) as the chromogen. 25 
 26 
Digitized histology: Whole-slide images were digitized using a NanoZoomer XR scanner 27 
(20x magnification, 0.46μm resolution, Hamamatsu, Japan). ROIs of viable tumor and 28 
necrosis for each sample were independently provided. Histology images were subsequently 29 
split into tiles of 2000x2000 pixels (jpeg). 30 
 31 
Picrosirius red staining segmentation: A macro was written in Fiji (https://fiji.sc/) to segment 32 
picrosirius red staining from each tile using ImageJ/Fiji plugins (Java 8). Images were first 33 
converted from the RGB color space into the green-red (a*) color channel of the CIELAB 34 
color space (lightness, green–red and blue–yellow), and subsequently thresholded to 35 
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and manual thresholding, two manual thresholds were chosen to achieve the optimal 1 
picrosirius red staining segmentation across all samples, whilst compensating for variations 2 
in staining intensity and complex background values associated with the different cancer 3 
pathologies. A threshold value of above +17 was used in the a* color channel for the 4 
majority of tumor types, increased to +23 for medulloblastomas and neuroblastomas arising 5 
in the GTML/Trp53KI/KI and Th-MYCN transgenic mice respectively, and subcutaneous luc-U-6 
87-MG tumors. The segmentation algorithm was tested using independent annotation, from 7 
a single observer blinded to the algorithm’s result, of stained/non-stained points (3920/3478) 8 
on 17 different samples across all cancer types, giving an accuracy of 95% with 91% 9 
sensitivity. 10 
 11 
Cell segmentation from H&E-stained sections: Images were processed using the EBImage 12 
Bioconductor package (33). Cell nuclei were extracted from each image tile using the Otsu 13 
thresholding algorithm, followed by morphological opening to delete the noisy structures and 14 
the Watershed algorithm to separate clustered nuclei (34).  15 
 16 
CD31 segmentation from CD31-stained immunohistochemistry sections: A macro was 17 
written in Fiji to extract DAB staining from each tile by applying color unmixing to extract the 18 
brown color channel, followed by application of the maximum entropy threshold detection 19 
method, both using ImageJ/Fiji plugins (Java 8) as previously described (27). 20 
 21 
Generation of collagen fraction, cellularity and vascular density parametric maps: Whole-22 
slide images of picrosirius red staining, segmented cells, and CD31 staining were converted 23 
into binary and processed to match MR elastography resolution (300x300μm), with the 24 
fraction of pixels occupied by the center of each cell nucleus, picrosirius red and CD31 25 
staining within 664x664 pixel-regions representing a single pixel in the final calculated maps. 26 
Quantitative analysis of each stain was performed from one histological tumor section 27 
aligned with the central slice of the elastogram. Necrotic areas visible on both T2-weighted 28 
images and corresponding histopathology slides were subtracted from the viable tumor by 29 
manual regional segmentation and excluded from the quantitative analysis.   30 
  31 
Texture analysis: We evaluated the two-dimensional heterogeneity of collagen distribution by 32 
quantifying entropy and fractal dimension (FD), as described by Nieskoski et al (35), on the 33 
extracted collagen parametric maps. The texture analysis was implemented in Matlab 34 
(R2018b, Mathworks, Natick, MA, USA). Necrotic areas were subtracted from the viable 35 
tumor and excluded from the analysis. Entropy was quantified to measure the irregularity of 36 
collagen distribution by applying the “entropy” function of Matlab, which uses the equation:  37 
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, where p represents the normalized histogram count of the collagen fraction. FD defines the 2 
complexity (textural roughness) of collagen distribution within the tumor samples. The 3 
Hausdorff (box-counting) method was applied in the histology images within the 664x664 4 
pixel-regions described earlier, using the equation:  5 





, where e represents the box size set to the size of the image and N(e) corresponds to the 8 
number of boxes of size ‘e’ which contain collagen. The median value of the generated FD 9 
maps (excluding necrotic areas) was used as the tumor’s FD value.  10 
 11 
 12 
Statistical Analysis 13 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software Inc., La 14 
Jolla, USA). Unless stated otherwise, data are presented as mean ± 1 s.e.m. Significant 15 
differences in quantitative MR elastography parameters between tumor types, and in relative 16 
treatment-induced changes, were identified using the non-parametric Mann-Whitney U-test 17 
with a 5% level of significance, whilst significant changes in MR elastography parameters 18 
with treatment were identified using the Wilcoxon matched-pairs signed ranks test with a 5% 19 
level of significance. Significant correlations were determined using linear regression 20 
analysis with a 5% level of significance using the robust regression and outlier removal 21 
approach (36). 22 
 23 
  24 
Research. 
on June 9, 2020. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 





MR elastography was successfully performed in all mice, yielding an intertumoral coefficient 3 
of variation (CoV) of 13.0 and 15.4 % for repeated measurements of Gd and Gl respectively 4 
(Supplementary methods). MR elastography revealed a heterogeneous distribution of 5 
elasticity and viscosity across the nine orthotopic and transgenic models of cancer 6 
investigated (Figure 1A). Pronounced contrast between the established tumor and the 7 
surrounding brain was clearly evident in the intracranial models, with the lesion boundaries 8 
aligning with those seen in the high-resolution T2-weighted images. Quantitative analysis of 9 
the MR elastography data demonstrated a wide range in Gd and Gl values across the 10 
models, from 3.5 ± 0.2 and 2.2 ± 0.2 kPa respectively in the GTML/Trp53KI/KI transgenic 11 
mouse model of medulloblastoma, to 7.9 ± 0.4 and 6.0 ± 0.2 kPa in the orthotopic luc-MDA-12 
MB-231 LM2-4 mammary carcinomas (Figure 1B). Collectively, elasticity and viscosity were 13 
significantly (p<0.0001) greater for the orthotopically-propagated breast and pancreas 14 
models, compared to the tumors associated with the central or peripheral nervous system.  15 
 16 
Intravenous injection of collagenase resulted in a clear overall reduction in the elasticity and 17 
viscosity of orthotopic MDA-MB-231 and BT-474 mammary tumors, as measured by MR 18 
elastography, 5 hours after administration (Figure 2A). Tumor regions exhibiting relatively 19 
high Gd and Gl pre-treatment were typically reduced following challenge with collagenase.  20 
No similar response was evident in the vehicle-treated mice. Collectively, collagenase 21 
resulted in a significant reduction in both Gd (6.0 ± 0.4 kPa to 4.9 ± 0.4 kPa, p=0.001) and Gl 22 
(3.8 ± 0.6 kPa to 3.0 ± 0.5 kPa, p=0.001), which was not observed in the vehicle-treated 23 
cohort (Gd: 5.1 ± 0.4 kPa to 5.4 ± 0.3 kPa, p=0.3; Gl: 3.0 ± 0.6 kPa to 3.4 ± 0.5 kPa, p=0.13). 24 
Relative changes in both Gd and Gl were significantly different between the collagenase and 25 
vehicle-treated cohorts (p=0.0008 and p=0.0004, Figure 2B).  26 
 27 
To investigate the pathological determinants of the regional variations in tumor viscoelasticity 28 
seen in vivo, parametric maps of Gd and Gl were compared with maps of picrosirius red 29 
(collagen I & III), H&E (cellularity) and CD31 (vascular density) staining, automatically 30 
segmented from high-resolution images of aligned tissue sections from the same tumor 31 
(Figure 3A). In the the GTML/Trp53KI/KI transgenic mouse model, which exhibited the lowest 32 
mean Gd and Gl, of all the models investigated, tumors presented with a thin layer-like region 33 
of elevated Gd and Gl spatially associated with strong picrosirius red staining adjacent to the 34 
skull, consistent with tumor invasion into the collagen-rich meninges (Figure 3B). In general, 35 
but especially in breast and pancreatic tumors, regions demonstrating high values of Gd and 36 
Gl spatially corresponded to cellular regions with higher deposition of collagen. In some 37 
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tumors, histologically-defined regions of extensive tissue damage (e.g. necrosis) were 1 
spatially associated with areas of markedly lower elasticity and viscosity. It is important to 2 
note the relative softness of these necrotic regions irrespective of their also having high 3 
collagen content. These regions were excluded from the subsequent quantitative analysis. 4 
Quantitative analysis identified statistically significant positive inter-tumor correlations of both 5 
tumor-mean elasticity Gd (r=0.72, p<0.0001) and viscosity Gl (r=0.78, p<0.0001) with tumor-6 
mean collagen fraction, but not with tumor-mean cellularity and vascular density (Figure 3C).  7 
 8 
The irregularity of collagen distribution and deposition, and its relationship to tumor 9 
viscoelasticity in vivo, was further investigated using texture analysis of the extracted images 10 
of picrosirius red staining. Significant negative correlations of entropy with Gd (r=-0.69, 11 
p<0.0001) and Gl (r=-0.76, p<0.0001), and positive correlations of FD with Gd (r=0.75, 12 
p<0.0001) and Gl (r=0.78, p<0.0001) were found (Figure 4A and B). Entropy values close to 13 
zero and relatively high values of FD determined in the BT-474, luc-PANC-1 and luc-MDA-14 
MB-231 LM2-4 tumors are consistent with the presence of a homogeneous and dense 15 
collagen network. Note that in the models investigated, increasing collagen content was 16 
associated with both increasing density and uniformity of its distribution, as shown by the 17 
mono-exponential relationship of entropy (y= 3.86e-0.24x, r2=0.76) and logarithmic relationship 18 
of FD (y= 0.15lnx + 1.16, r2=0.98) with collagen fraction, respectively (Figure 4C). 19 
 20 
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ECM stiffening is increasingly recognized as a major mechanical signal, which alters cell 3 
behavior and in part confers to cancer cell hallmark capabilities including sustained growth, 4 
invasion and metastasis (6,7,37-42). ECM stiffening is also associated with increased solid 5 
stress and IFP, two other hallmarks of tumor mechanobiology that induce blood and 6 
lymphatic vessel compression, and reduced transcapillary transport respectively, and which 7 
impair effective drug delivery (3). Disrupting the crosstalk between cancer cells and the 8 
ECM, as well as reversing ECM stiffness, solid stress or IFP, thus represents a promising 9 
therapeutic strategy (11). The clinical development of stromal modulating therapies would be 10 
facilitated and accelerated by non-invasive imaging methods to longitudinally image and 11 
quantify tumor mechanical properties in vivo (15-17). 12 
 13 
In this pre-clinical study, our quantitative MR elastography tumor data, combined with 14 
aligned computational histopathology, showed that elevated tumor Gd and Gl correlated with 15 
increased collagen deposition across a wide range of clinically-relevant tumor models with 16 
disparate pathologies. Our data particularly highlight the relative softness of tumors arising in 17 
the nervous system, and the predicted elevated stiffness of orthotopic breast and pancreatic 18 
models. Furthermore, modulation of the collagen network with bacterial collagenase in two 19 
relatively stiff orthotopic models of breast cancer reveal a marked reduction in both elasticity 20 
and viscosity. Collectively our results demonstrate that the deposition and density of the 21 
collagen fiber network is a major determinant of the tumor biomechanical phenotype, for 22 
which MR elastography provides sensitive in vivo imaging biomarkers, including biomarkers 23 
of its pharmacological modulation.  24 
 25 
Our MR elastography study also aligns with several established concepts in tissue 26 
mechanics. The elastic properties of tissues are defined by the mechanical characteristics of 27 
their cells and their surrounding ECM, yet tissue macroscopic viscoelastic properties are not 28 
greatly affected by differences in cell morphology and density, but are largely governed by 29 
their ECM composition (43). Herein, histologically-confirmed regions of tissue damage 30 
(necrosis) were associated with markedly reduced elasticity and viscosity visualized in vivo. 31 
This relation is irrespective of the collagen fraction within the necrotic regions and explains 32 
the heterogeneous appearance of the viscoelastic maps, as well as the absence of spatial 33 
correspondence with the homogenous network of collagen in the luc-PANC-1 tumors, which 34 
exhibit marked and widespread regions of multifocal discrete necrosis. This is also 35 
consistent with previous MR elastography studies reporting a reduction in viscoelastic 36 
properties following vascular targeted-therapy induced cell death and/or reduction in 37 
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vascular density (18,20,21). Whilst this demonstrates the importance of both a viable cellular 1 
and vascular network to tissue integrity and mechanopathology, our data show they provide 2 
a very moderate contribution to the observed range of mechanical phenotypes, in contrast to 3 
differences in ECM characteristics.  4 
 5 
Intracranial tumors were typically at the softer end of the spectrum of viscoelastic properties 6 
measured in this study (Gd ~4kPa and Gl ~2kPa) (19,22). The high compliance (inversely 7 
related to elastic modulus) of human brain tumors relative to the surrounding brain 8 
parenchyma has been reported, and in the case of glioblastoma, stiffness has been shown 9 
to decrease with tumor grade, measured as part of clinical MR elastography-embedded 10 
prospective studies (44,45). Brain tumors share the unique composition of the healthy brain, 11 
characterized by the absence of a fibrillar network (which resists shear deformation) and a 12 
reliance on hygroscopic hyaluronic acid (the main mechanical support against compressive 13 
forces that act to cause a change in volume but offer little resistance to shear) for 14 
mechanical support.  The lack of collagen, a major facilitator of tumor cell intravasation, one 15 
of the earliest stages of metastasis, is consistent with the fact that intracranial tumors rarely 16 
disseminate outside the brain (46). Note also the relatively low viscoelastic properties of the 17 
intracranially grown luc-MDA-MB-231 LM2-4 tumors compared to those propagated in the 18 
mammary fat pad, highlighting the contribution of implantation site to the resulting 19 
biomechanical phenotype. Abdominal neuroblastomas spontaneously arising in Th-MYCN 20 
transgenic mice, and which are derived from the sympathetic nervous system, were also 21 
relatively soft with little collagen, consistent with their general clinical presentation (47). 22 
Interestingly, increased collagen III (reticulin) deposition helps to define an ultra-high-risk 23 
group of patients in which increased stiffness relates to metastatic potential, the major cause 24 
of mortality for children with neuroblastoma (48,49).  25 
 26 
MR elastography revealed an acute reduction in breast tumor elasticity and viscosity 27 
following systemic administration of collagenase. A similar biomechanical response was 28 
recently reported following intratumoral injection of collagenase, measured using US-based 29 
elastography (16). Collagenase has also been shown to rapidly decrease tumor IFP in 30 
breast cancer xenografts (50,51). Cleavage of collagen with collagenase produces large 31 
peptide fragments which remain trapped within the ECM, making the acute effects of 32 
collagenase challenging to detect on conventional histology at such an acute time point (12). 33 
Having established their dependence on relative tumor collagen fraction, quantitation of 34 
tumor Gd and Gl can also provide early MRI biomarkers of response to collagen degradation 35 
in vivo. In this way, MR elastography could thus be exploited for monitoring direct enzymatic 36 
degradation of the ECM and/or targeted inhibition of collagen synthesis, potent strategies 37 
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being actively investigated to improve drug penetration in solid tumors, and showing 1 
promising results in clinical trials (10,12,52). 2 
 3 
Solid stress has been shown to correlate with collagen deposition and be the major 4 
contributor to total tumor pressure in models of pancreatic cancer (53). ECM stiffening is a 5 
marker of poor prognosis in breast cancer and pancreatic ductal adenocarcinoma 6 
(6,37,38,40). Given its sensitivity to collagen deposition, MR elastography may thus 7 
potentially provide prognostic information, and through its sensitivity to collagen modulation, 8 
provide biomarkers of response to collagen-targeted approaches designed to alleviate solid 9 
stress for improved drug delivery. Tumor shear modulus, measured by US elastography, has 10 
been shown to positively correlate with collagen deposition and inversely correlate with 11 
functional vasculature and drug delivery (17). However, MR elastography cannot measure 12 
pressure directly, and as such may not be directly informative for strategies designed to 13 
decrease fluid stress (e.g. hyaluronidase), for which direct measurements of IFP are 14 
required. Reconstruction of tumor viscoelastic parameters from the properties of propagating 15 
waves or strain visualized by MRI or US has often used a simple monophasic linear 16 
viscoelastic mechanical model, which does not take in account any mobile fluid component 17 
(54). Measuring IFP and solid stress in itself represents a major clinical challenge, as current 18 
approaches for measuring both are invasive. Clinical measurement of IFP with wick-in-19 
needles only permits very discrete sampling of the tissue and is unreliable, whilst innovative 20 
pre-clinical MRI methods shown to correlate with IFP in vivo would be difficult to routinely 21 
implement in a clinical setting (51,55).  22 
 23 
Finally, the utility of MR elastography is being actively evaluated clinically in a wide range of 24 
health conditions including neuro- and cardiovascular pathologies, with applications 25 
including diagnosis, staging, surgical planning and intraoperative guidance. For example, the 26 
integration of MR elastography into the management of patients with chronic liver disease is 27 
now becoming well established for its excellent diagnostic accuracy, superior to that of US-28 
based techniques, and ability to discriminate the different stages of liver fibrosis, 29 
characterized by increased deposition and crosslinking of collagen (56). Whilst less widely 30 
available and more costly than US-based techniques, MR elastography does allow the three 31 
dimensional investigation of large tissue areas and deep-seated organs. MR elastography 32 
can uniquely afford the non-invasive investigation of the mechanical properties of the brain 33 
and its pathology, including as recently demonstrated, neuronal activity (57). Lastly, MR 34 
elastography can be incorporated into multiparametric MR imaging protocols to enable 35 
comparison with other MRI-derived biomarkers of tumor structure and function in a single 36 
clinical scanning session. 37 
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In conclusion, we have shown that quantitation of elasticity Gd and viscosity Gl are sensitive 2 
imaging biomarkers of tumor collagen deposition, and response to direct enzymatic 3 
degradation of the collagen network. Given the importance of elevated ECM stiffness in 4 
tumor progression, and the continuing need for new technologies for faster and more 5 
accurate detection, diagnosis and monitoring, MR elastography has the potential to inform 6 
non-invasively on prognosis and improve risk stratification of cancer patients with dense 7 
stroma, and accelerate the development of stromal targeting/modulating treatment 8 
strategies.  9 
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Table 1. Summary of the in vivo models  1 
 2 
*Tumor volumes at the time of the MR elastography experiment and determined using segmentation from regions 3 
of interest drawn on each tumor-containing T2-weighted MRI slice. i.c. intracranial, o.t. orthotopic, s.c. 4 
subcutaneous 5 
 6 
  7 
  








Highly malignant human 
triple negative breast 




i.c. 5 x 103 5 29 ± 8  
MRE-histology 
correlation 
o.t.  2 x 106 6 406 ± 47 
luc-RG2 Rat glioma cells  MRE-histology 
correlation 
o.t. 5 x 103 5 30 ± 4 
luc-U-87 MG Human glioblastoma cells  MRE-histology 
correlation 
i.c.  5 x 104 8 26 ± 4 
MRE-histology 
correlation 
s.c 3 x 106 6 616 ± 114 
 





i.c. 1.5 x 105 7 12 ± 3 
MDA-MB-231 Highly malignant human 




o.t. 2 x 106 14 385 ± 49 




o.t. 5 x 106 7 438 ± 36 
Collagenase 
treatment 
o.t. 5 x 106 7 287 ± 50.8 




o.t. 1 x 107 7 1402 ± 280 
Transgenic mouse models 




5 1369 ± 254 




7 27 ± 4 
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Figure legends 1 
 2 
Figure 1.  MR elastography reveals marked differences in viscoelasticity measured in 3 
vivo in orthotopic and transgenic models of cancer.  (A) Representative T2-weighted 4 
MRI and associated parametric maps of elasticity Gd and viscosity Gl obtained from a 5 
medulloblastoma spontaneously arising in the brain of a GTML/Trp53KI/KI transgenic mouse 6 
(n=7), intracranially (i.c.) propagated luc-MDA-MB-231 LM2-4 breast cancer (n=5) and luc-D-7 
212-MG glioblastoma xenografts (n=7), a neuroblastoma spontaneously arising in a Th-8 
MYCN transgenic mouse (n=5), intracranially propagated luc-RG2 (n=5) and luc-U-87 MG 9 
glioblastoma xenografts (n=8), and orthotopic BT-474 breast cancer (n=7), luc-PANC1 10 
pancreatic cancer (n=7) and luc-MDA-MB-231 LM2-4 breast cancer (n=6) xenografts.  The 11 
dashed line (---) indicates the tumor boundaries defined on T2-weighted images.  (B) 12 
Quantitative summary of mean of the mean tumor Gd and Gl (± 1 s.e.m) for each model.  13 
The insets show that the collective average of Gd and Gl determined in the breast and 14 
pancreatic tumors was significantly higher than in tumors arising in the nervous system 15 
(****p<0.0001). 16 
 17 
Figure 2. MR elastography can inform on tumor stromal modulation induced by 18 
collagenase.  (A) Representative T2-weighted anatomical MRI images, and parametric 19 
maps of Gd and Gl, acquired from mice bearing orthotopic BT-474 breast cancer xenografts 20 
24 hours prior to and 5 hours after intravenous injection of either vehicle or collagenase.  (B) 21 
Relative changes (%) in tumor median Gd and Gl measured in orthotopic MDA-MB-231 (blue 22 
symbols) and BT-474 (red symbols) breast cancer xenografts measured 5 hours after 23 
administration of either vehicle () or collagenase ().  Data are the individual changes 24 
from each tumor, and the combined cohort mean ± 1 s.e.m.  Collagenase induced a 25 
significant reduction in both Gd and Gl compared to vehicle control. 26 
 27 
Figure 3. MR elastography-derived elasticity Gd and viscosity Gl correlate with tumor 28 
collagen fraction. Representative anatomical T2-weighted MRI images and parametric 29 
maps of elasticity (Gd) and viscosity (Gl), and the corresponding computed maps of 30 
picrosirius red staining (collagen I & III), hematoxylin and eosin staining (cellularity) and 31 
immunohistochemical detection of Cd31 (vascular density) extracted from high-resolution 32 
images of tissue sections from: (A) a medulloblastoma spontaneously arising in the brain of 33 
a GTML/Trp53KI/KI transgenic mouse, a neuroblastoma spontaneously arising in a Th-MYCN 34 
Research. 
on June 9, 2020. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 11, 2019; DOI: 10.1158/0008-5472.CAN-19-1595 
 
 23 
transgenic mouse, and an intracranially propagated luc-U87-MG glioblastoma xenograft, and 1 
(B) from orthotopic BT-474, luc-PANC-1 and luc-MDA-MB-231 LM2-4 breast and pancreatic 2 
cancer xenografts. Note that the areas above the brain tumors showing both high 3 
viscoelastic properties and high picrosirius red staining correspond to regions where the 4 
tumor has invaded the collagen-rich meninges. Dotted lines indicate regions of necrosis. 5 
Note that in necrotic areas, high collagen density is not associated with high value of Gd and 6 
Gl. (C) Scatter graphs of individual tumor mean Gd and Gl plotted against mean collagen 7 
fraction (%), cellularity and vessel density. Linear regression analysis and 95% confidence 8 
intervals for significant correlations are shown.   9 
 10 
Figure 4.  The relationship between MR elastography-derived tumor viscoelastic 11 
properties and the spatial distribution and deposition of collagen evaluated by texture 12 
analysis.  Scatter graphs of individual mean tumor elasticity Gd and viscosity Gl plotted 13 
against (A) entropy and (B) fractal dimension (FD).  Linear regression analysis and 95% 14 
confidence intervals for significant correlations are shown. Note that both Gd and Gl are 15 
negatively correlated with entropy and positively correlated with FD, indicating that increased 16 
tumor stiffness is associated with more complex and more homogenously distributed 17 
collagen. Entropy values close to zero and relatively high values of FD determined in the BT-18 
474, luc-PANC-1 and luc-MDA-MB-231 LM2-4 tumors are consistent with the presence of 19 
such a homogeneous and dense collagen network. (C) Scatter graphs showing the mono-20 
exponential relationship between entropy and collagen fraction (y= 3.86e-0.24x, r2=0.76), and 21 
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